Biocon Gets FDA Observations At Key Biosimilars Facilities
US Agency Finds Multiple Form 483 Deficiencies Across Bengaluru And Malaysia Sites
• By David Wallace
Biocon has received multiple Form 483 observations across three facilities • Source: Shutterstock 
